UNC Health Medication Formulary
Add Formweb to your mobile device
UNC Health Medication Formulary
System Formulary Update
Oral Oncolytic Agents
Situation
The oral oncolytic agents class review and formulary standardization was approved by the System Pharmacy & Therapeutics Committee in March 2022.
Background
The following medications were reviewed: capecitabine (Xeloda), erlotinib (Tarceva), lomustine (Gleostine), dasitinib (Sprycel), nilotinib (Tasigna)
Assessment/Recommendation
Changes effective: Tuesday, April 26th
System P&T voted to include the following products on the UNC Health Care System Drug Formulary:
- Capecitabine (Xeloda) 150 mg tablets and 500 mg tablets. Orders must be signed by a Hematology/Oncology Attending Physician.
- Dasitinib (Sprycel) 70 mg and 100 mg tablets. Orders must be signed by a Hematology/Oncology Attending Physician.
System P&T voted to exclude the following products on the UNC Health Care System Drug Formulary:
- Erlotinib (Tarceva) 25 mg and 100 mg tablets
- Dasitinib (Sprycel) 20 mg, 50 mg, and 140 mg tablets
- Lomustine (Gleostine) 10 mg and 40 mg capsules
- Nilotinib (Tasigna) 150 mg and 200 mg capsules
Note: Stock of these formulary products may vary at individual entities